Evidence map›Paper›PMID 42243530›Full record

ArticleExperimental & molecular medicine2026

Transferrin receptor 1 shedding by the pro-inflammatory iRhom-ADAM17 complex and ADAM10 regulates cellular iron uptake and ferroptosis.

Katharina Schun, Cindy Rinkens, Daniel Mehling, Yan Yu, Sarah Knapp, Carolin Peschke, Friederike Sonnabend, Christine Lux, Alessa Pabst, Laura Charlier and 4 more

Abstract read
In one paragraph

Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Katharina SchunInstitute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Aachen, Germany.ORCID http://orcid.org/0000-0002-5552-1036
Cindy RinkensInstitute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Daniel MehlingInstitute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Yan YuInstitute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Sarah KnappInstitute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Aachen, Germany.ORCID http://orcid.org/0009-0008-3398-6917
Carolin PeschkeInstitute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Friederike SonnabendInstitute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Christine LuxInstitute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Alessa PabstInstitute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Laura CharlierInstitute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Neele SchumacherInstitute of Biochemistry, Medical Faculty, Kiel University, Kiel, Germany.
Aaron BabendreyerInstitute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Andreas LudwigInstitute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Stefan DüsterhöftInstitute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Aachen, Germany. stefan.duesterhoeft@hmu-duesseldorf-krefeld.de.ORCID http://orcid.org/0000-0002-6926-136X

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 418426903Deutsche Forschungsgemeinschaft (German Research Foundation) Research Fellowship (280679981)Rheinisch-Westfälische Technische Hochschule Aachen | Medizinische Fakultät, RWTH Aachen University (Medical Faculty, RWTH Aachen University) START grant (#691903-06/19)Rheinisch-Westfälische Technische Hochschule Aachen | Medizinische Fakultät, RWTH Aachen University (Medical Faculty, RWTH Aachen University) START grant (#692230-102/22)Rheinisch-Westfälische Technische Hochschule Aachen | Medizinische Fakultät, RWTH Aachen University (Medical Faculty, RWTH Aachen University) START grant (#692305-06/23)Rheinisch-Westfälische Technische Hochschule Aachen | Medizinische Fakultät, RWTH Aachen University (Medical Faculty, RWTH Aachen University) START grant (#692325-002/23)RWTH Aachen University (Rheinisch-Westfälische Technische Hochschule Aachen) ERS Start-up (StUpPD_299-18)RWTH Aachen University (Rheinisch-Westfälische Technische Hochschule Aachen) Graduate Support
6 · The paper itself

Abstract

Iron homeostasis is a tightly regulated mechanism, wherein the uptake, transport, storage and export of iron are stringently controlled. Dysregulation and excessive iron uptake lead to iron-dependent programmed cell death called ferroptosis, a promising future cancer therapy target. Cellular iron uptake is limited by the surface presence of membrane-bound transferrin receptor 1 (TfR1). Soluble TfR1 is used as a major clinical marker to differentiate anemia types. Here we identify iRhoms, the regulatory interactors of the surface protease ADAM17, as substrate platforms. They bind TfR1 and facilitate ADAM17-mediated proteolytic TfR1 release (TfR1 shedding). Thereby, the iRhom-ADAM17 complex regulates TfR1 surface levels. Notably, TfR1 preferentially binds to pro-inflammatory iRhom2 over iRhom1, with the cytosolic N terminus of iRhom serving as a critical binding determinant. By CRISPR-Cas9-based knockout and pharmacological inhibition in vitro, in human primary endothelial cells as well as in ex vivo human lung slices, we also demonstrate that TfR1 is a shared substrate of ADAM10 and ADAM17. Functionally, we found that ADAM17-dependent TfR1 shedding reduces excessive iron uptake. By live cell imaging, we identified TfR1 shedding as a protective mechanism against ferroptosis. Moreover, reduced TfR1 shedding correlaśtes with elevated serum iron levels in ADAM17-hypomorphic mice, highlighting its systemic relevance for patho(physiological) iron homeostasis. iRhom-ADAM17 complex and ADAM10-shed TfR1. Cellular iron uptake is facilitated by TfR1. TfR1 interacts with the substrate platform iRhom, which is a regulator of the protease ADAM17. The iRhom-ADAM17 complex and ADAM10 cleave TfR1, thereby releasing soluble TfR1. By this, iron overloaded is prevented. Therefore, ectodomain shedding of TfR1 is a protective mechanism to hinder ferroptosis.

Indexed as

ADAM10 ProteinADAM17 ProteinAmyloid Precursor Protein SecretasesAntigens, CDCarrier ProteinsFerroptosisIronMembrane ProteinsReceptors, TransferrinAnimalsHumansIntracellular Signaling Peptides and ProteinsMiceADAM10 ProteinADAM10 protein, humanADAM17 ProteinADAM17 protein, humanAdam17 protein, mouseAmyloid Precursor Protein SecretasesAntigens, CDCarrier ProteinsCD71 antigenIntracellular Signaling Peptides and ProteinsIronMembrane ProteinsReceptors, TransferrinRHBDF2 protein, human

Identifiers

PMID42243530
PMCPMC13324561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.